Precise Neoadjuvant Chemoresection of Low Grade NMIBC

Based on the unmet clinical need to reduce invasiveness of treatment of low grade NMIBC, the investigators conduct this prospective, open label, single arm and single center phase II trial. The investigators aim to use drug screens in PDOs to guide neoadjuvant intravesical instillation therapy with either Epirubicin, Mitomycin C, Gemcitabine or Docetaxel to achieve chemoresection NMIBC.

NCT Number	NCT06227065
Lead Sponsor	University of Bern Collaborators: Spitalzentrum Biel
Conditions	Bladder Cancer, Non-muscle Invasive Bladder Cancer, Low-risk
Enrollment	28 participants
Start Date	2024-10
Primary Completion	2026-10 (estimated)
Study Completion	2029-10 (estimated)
Updated on ClinicalTrials.gov	2024-01-26